Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (53 quarters reported)
$3.18B in Q2 2013 → $931M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Cava Group Inc | 54.9% | Trimmed 32% | 6,507,990 | $511M |
| Lexicon Pharmaceuticals Inc | 45.1% | Added 13% | 175,156,062 | $420M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cava Group Inc | Trimmed | −3,000,000 | −$235M | 54.9% |
| Lexicon Pharmaceuticals Inc | Added | +20,421,735 | +$49M | 45.1% |
quarter ended March 31, 2026 · filed May 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc | Added | +18,553,846 | +$28.9M | 23.9% |
quarter ended December 31, 2025 · filed February 12, 2026
No position changes this quarter.
quarter ended September 30, 2025 · filed November 12, 2025
No position changes this quarter.
quarter ended June 30, 2025 · filed August 13, 2025
No position changes this quarter.
quarter ended March 31, 2025 · filed May 14, 2025
No position changes this quarter.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cava Group Inc | Trimmed | −8,000,000 | −$902M | 91.4% |
quarter ended September 30, 2024 · filed November 13, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cava Group Inc | Trimmed | −6,000,000 | −$743M | 91.0% |
| Scholar Rock Holding Corp | Exited | −11,259,438 | −$93.8M | — |
| Kymera Therapeutics Inc | Exited | −3,005,610 | −$89.7M | — |
| Morphic Holding Inc | Exited | −2,525,998 | −$86.1M | — |
| Arrowhead Pharmaceuticals Inc | Exited | −3,189,389 | −$82.9M | — |
| Lexicon Pharmaceuticals Inc | Trimmed | −38,918,903 | −$61.1M | 9.0% |
| Apellis Pharmaceuticals Inc | Exited | −1,467,080 | −$56.3M | — |
| Dyne Therapeutics Inc | Exited | −1,516,960 | −$53.5M | — |
| Silence Therapeutics PLC | Exited | −2,779,619 | −$52.8M | — |
| Springworks Therapeutics Inc | Exited | −1,313,026 | −$49.5M | — |
Showing the 10 largest of 112 changes.
Loading...
